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Introduction
Ferulic acid [trans-4-hydroxy-3-methoxycinnamic acid] (FA) is 
a naturally found phenolic acid that is abundantly bound to most of 
the foods consumed by humans (bran, whole grains, fruits, vegetables, 
tea, coffee). This molecule is a potent antioxidant able to neutralize free 
radicals, such as Reactive Oxygen Species (ROS) [1] which have been 
implicated in DNA damage [2], cancer[3], accelerated cell aging [4], 
obesity[5] and type 2 diabetes mellitus (T2DM) [5,6]. A number of gas-
trointestinal tract (GIT) bacterial strains have been shown to produce 
feruloyl esterase (FAE) [7-12], an enzyme that hydrolyses and releases 
free FA from its bound state. Orally ingested FA-producing lactic acid 
bacteria should demonstrate an increased bioavailability of FA due to 
increased FAE activity in the intestine. Live microorganisms have been 
ingested and fermented in foods for centuries, with Metchnikoff estab-
lishing the concept of probiotics in the early 1900s [13]. Unfortunately, 
probiotic survival incorporated in foods is usually low due to the harsh 
environment (low pH, digestive enzymes, bile) of the GIT. Microencap-
sulation in polymer membranes, such as alginate-polylysine-alginate 
(APA) has been shown to successfully protect live bacterial cells for oral 
delivery [8,11,14]. Specifically, the microencapsulation of FAE bacteria 
has demonstrated a higher viable cell count delivery through the GIT, 
allowing for a higher FA bioavailability [8,9,11].Previous research by 
our group has demonstrated that microencapsulated Lactobacillus fer-
mentum ATCC 11976 (L.f. 11976) can be used as a probiotic formula-
tion in the context of cholesterol management in a Bio F1B hypercho-
lesterolemic Golden Syrian hamster model [9].
The increased bioavailability of FA in the GIT may also induce ad-
ditional metabolic changes which should prove beneficial for the treat-
ment of metabolic syndrome, specifically T2DM, obesity and cardiovas-
cular diseases. T2DM and obesity are two major public health concerns 
in industrialized countries. The prevalence of diabetes in the United 
States in 2005 was estimated at 16.2 million individuals and is projected 
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Abstract
Ferulic Acid (FA) is a natural phenolic acid produced by a number of lactic acid bacteria. FA has a number of 
beneficial properties, including: antioxidant activity, anti-tumorigenic properties and cholesterol-lowering capabilities. 
Our group has previously screened lactobacilli for FA production, and selected L. fermentum ATCC 11976 (L.f. 
11976) as one of the best producers. Alginate-polylysine-alginate (APA) microencapsulation has proven successful 
for the oral delivery of this strain to the colon, where production of FA is greatest. The aim of this study was to 
investigate the role of APA microencapsulated L.f. 11976 to modulate markers of metabolic syndrome. The antioxidant 
activity, as a potential mechanism of action to treat/prevent metabolic syndrome of free and microencapsulated L.f. 
11976 was quantified. A high-fat fed BioF1B Golden Syrian hamster model was used to investigate the effects of 
orally administered microencapsulated L.f. 11976 on markers of metabolic syndrome. Results demonstrate that 
the microencapsulated L.f. 11976 formulation greatly reduced the adiposity index (p = 0.0014), serum insulin (p = 
0.0042), insulin resistance (p = 0.0096), glycosylated albumin (p = 0.00013), serum leptin (p = 0.048), serum uric acid 
(p =0.025) serum total cholesterol (p = 0.024), serum esterified cholesterol (p = 0.0328) and free non-esterified fatty 
acid (p = 0.029) levels in the treated animals. This research indicates that the probiotic L.f. 11976 microencapsulated 
formulation may significantly delay the onset of insulin resistance, hyperglycemia, hyperinsulinemia, dyslipidemia 
and obesity, indicating a lower risk of diabetes and cardiovascular disease. We propose and discuss the potential 
mechanism(s) of action by which FA is acting. With these in mind, further in vivo studies are required to validate the 
therapeutic effects of the formulation and to investigate the mechanism(s) of action by which the probiotic formulation 
is acting.
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to rise to 48.3 million individuals by 2050 [15]. Obesity, also related to 
T2DM, is an epidemic, not only because of its increasing prevalence 
but, also because of its frequent association with major atherosclerotic 
and cardiovascular risk factors [16]. As a potential natural therapeutic, 
FA has been shown to regulate blood glucose levels through a variety of 
mechanisms including the modulation of insulin secretion, the promo-
tion of pancreatic beta-cell survival and the reduction of inflammatory 
markers linked to antioxidant activity [17]. With these properties in 
mind, FA could provide a way to modulate hyperglycemia, hyperinsu-
linema, adiposity and other markers involved in a number of metabolic 
diseases, including T2DM and obesity.
The presented research attempts to demonstrate the antioxidant 
properties of a commercially available FA, to subsequently investigate 
the antioxidant potential of L.f. 11976, associated with its growth in 
ethyl ferulate (EFA), a natural substrate of FAE. Furthermore, we in-
vestigate, in vivo, the use of the FA-producing L.f. 11976 microencap-
sulated formulation to modulate markers involved in the pathogenesis 
of metabolic disorders such as T2DM and obesity using a diet-induced 
hypercholesterolemic hamster model.
Materials and Methods
Bacterial growth media and chemicals
EFA (ethyl 4-hydroxy-3-methoxycinnamate), FA, poly-l-lysine, 
calcium chloride and low viscosity sodium alginate were purchased 
from Sigma-Aldrich (Oakville, ON, Canada). De Man-Rogosa-Sharpe 
(MRS) broth was obtained from Fisher Scientific (Ottawa, ON, Cana-
da). Water was purified with an EASYpure Reverse Osmosis System and 
a NANO pure Diamond Life Science (UV/UF) ultrapure water system 
from Barnstead/Thermoline (Dubuque, IA, U.S.A.). All other chemi-
cals were of analytical or High-Performance Liquid Chromatrography 
(HPLC) grade and purchased from commercial sources.
Bacterial strain and culture conditions
L.f. 11976 was purchased from Cedarlane Laboratories (Burlington, 
ON, Canada). The bacterial strain was stored at -80°C in MRS contain-
ing 20% (v/v) glycerol. An MRS-agar plate was streaked for isolation 
from the frozen stock and incubated at 37°C with 5% CO2 for 24 h to 
ensure purity. One colony from the MRS-agar plate was inoculated into 
5mL of MRS broth and incubated at 37°C for 24 h. A 1% (v/v) inoculum 
was then used for subculturing and incubated at 37°C for 24 h immedi-
ately before use. Viability of microcapsules was estimated by exposure 
to 0.1 M sodium citrate until complete disruption of the microcapsules 
was observed. Ten-fold serial dilutions in physiological saline followed 
by plating on MRS-agar plates were then performed to determine the 
colony forming units.
APA microencapsulation of L.f. 11976
The microencapsulation of L.f. 11976, using APA polymer, was 
performed according to the standard protocol, described in our previ-
ous studies [8,11]. The microencapsulation procedure was performed 
using an Inotech encapsulator (Inotech Biosystems International, MD, 
U.S.A.) and optimal flow rate, vibration frequency and voltage. The 
semi-permeable microcapsules obtained have a molecular weight cut-
off of 60-70kDa, as previously demonstrated [8]. Microcapsules termed 
“empty,” which do not contain bacteria were also prepared as controls. 
Microencapsulated lactobacilli were stored at 4°C, in minimal media 
consisting of 10% MRS until further use. Previous work demonstrated 
no significant loss of cell viability or changes in microcapsule stability 
using this storage method [7].
Total antioxidant capacity of L.f. 11976
The total antioxidant production of L.f. 11976 was measured using a 
QuantiChromTM Antioxidant Assay Kit (BioAssay systems, CA, U.S.A.), 
a spectrophotometric assay based on the reduction of Cu2+ to Cu+ mea-
sured using a UV spectrophotometer Victor3V 1420 Multi label Coun-
ter (Perkin Elmer, MA, U.S.A.). The protocol provided with the assay 
kit was followed. A standard curve was generated for Trolox, a standard 
provided with the kit, at concentrations of 0, 300, 600 and 1000 μM 
plotted against absorbance at 570nm (R2=0.9970). Antioxidant activity 
of commercially available FA at concentrations of 0.3, 0.6, 0.9, 1.2 and 
1.5mM was plotted against Trolox concentrations at an absorbance of 
570nm. Unencapsulated L.f. 11976 was subcultured from MRS broth at 
1% (v/v) and microencapsulated L.f. 11976 at a concentration of 0.05g/
mL was added to MRS-EFA broth at an EFA concentration of 1.5mM.
Uninoculated MRS-EFA broth was used as a negative control. At each 
time point, the viability of the microcapsules and free cells was deter-
mined using ten-fold serial dilutions in physiological saline followed by 
plating on MRS-agar plates. Bacterial supernatant was obtained from 
each sample by centrifuging at 4000 rpm at 4°C for 15 minutes. The su-
pernatant was stored at 4°C until the assay was performed. All samples 
and controls were treated in triplicate and incubated at 37°C during the 
course of the experiment. 
Animals
Male Bio F1B Golden Syrian hamsters, 8 weeks old (BioBreeders, 
MA, U.S.A.) with an average body weight of 90 g were used in this 
study. The animals were housed three per cage in a climate controlled 
space with inversed, alternating light and dark cycles (12:12-hr light- 
dark cycle; lights on at 19:00). All the principles of laboratory animal 
care were followed and all of the experimental protocols complied with 
the Animal Care Committee of McGill University (Montréal, Canada) 
and the Canadian Council on Animal Care guidelines.
Animal diet and experimental protocol
Upon their arrival, animals were allowed free access to a commer-
cial rodent ration (LabDiet® Rodent Laboratory Chow 5001, Purina 
Laboratories, St. Louis, MO, U.S.A.) and water for 2 weeks during their 
acclimatization period. Baseline values of serum Total Cholesterol (TC) 
were determined, as described below, at the end of the acclimatization 
from hamsters fasted over a 14-hour period. These basal serum TC val-
ues were used to randomize the hamsters into the two treatment groups.
Following randomization, the hamsters of both groups were fed 
a semi-purified hyperlipidemic hypercholesterolemic diet ad libitum 
(Modified LabDiet® Laboratory Rodent Diet 5001 with 10.0% Wheat 
Bran, 0.05% Cholesterol, 6.0% Saturated Fat and 10.0% Total Fat, Pu-
rina Laboratories, St. Louis, MO, U.S.A.). To investigate the therapeu-
tic efficacy of the formulation, animals in the treatment group (n=12) 
received the microcapsule formulation containing 1011cfu of L.f. 11976 
twice daily, a dose determined from previous work by our group [9]. 
The control group (n = 12) received empty microcapsules as treatment 
vehicle-control. The treatment was administered during 10 weeks, 
with the hamsters orally fed the formulation using an 18G/50mm with 
2.25mm ball diameter stainless steel gavage needle. During the course 
of the treatment, food consumption and body weight were measured 
biweekly. Blood samples were collected once every 14 days from 14-
hour food-deprived hamsters via the saphenous vein. At the end of the 
experimental period, the hamsters were euthanized by carbon dioxide 
asphyxiation and blood was withdrawn by cardiac puncture.
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Biological samples
Blood was collected either in Microtainer® serum separator tubes 
or in Vacutainer® plasma tubes with spray-coated lithium heparin from 
Fisher Scientific (Ottawa, ON, Canada). For serum, the blood was al-
lowed to clot at 23°C for 30 minutes and subsequently placed on ice 
until centrifugation. Serum was separated by low-speed centrifugation 
at 2000xg for 20 min at 4°C temperature and stored at -80°C until used. 
To calculate the adiposity index, the weights of the epididymal, visceral 
and retroperitoneal fat were taken following their careful dissection. 
The adiposity index was calculated using the formula [Visceral fat/
(body weight-visceral fat)] *100, and expressed as adiposity percentage 
[18].
Clinical chemistry analysis
Serum lipids (TC, triglycerides), glucose, uric acid, glycosylated 
hemoglobin (HbA1c) and C-Reactive Protein (CRP) were assayed by 
conventional enzymatic methods on a Hitachi 911 automated clinical 
chemistry autoanalyzer (Roche Diagnostics, U.S.A.) using reagent kits 
supplied by Roche Diagnostics (Laval, QC, Canada). Serum Free Cho-
lesterol (FC) and Non-Esterified Fatty Acids (NEFA) were similarly es-
timated using reagent kits from Wako Chemicals Inc. (Richmond, VA, 
U.S.A). Serum insulin and leptin were measured by an Enzyme Immu-
noassay kit from SPI-BIO (Massy, France). Glycosylated albumin (GA) 
was estimated using a Glycaben ELISA kit from Exocell Inc. (Philadel-
phia, PA, U.S.A.).Fasting serum insulin and glucose were used to cal-
culate insulin resistance from the homeostasis model assessment for 
insulin resistance (HOMA-IR) [(fasting glucose * fasting insulin)/22.5] 
[19]. Serum cholesteryl ester (EC) concentrations were calculated as 
the difference between the TC and the FC concentrations. 
Statistical analysis
Experimental results are expressed as mean ± SEM. Statistical 
analysis was carried out using SPSS Version 17.0 (Statistical Product 
and Service Solutions, IBM Corporation, New York, NY, USA). Linear 
regression was performed to correlate FA and Trolox concentrations. 
Statistical comparisons were carried out using the Independent Sam-
ples t-test to compare the means of the treatment and control groups. 
Statistical significance was set at p < 0.05 and p-values less than 0.01 
were considered highly significant.
Results
Microencapsulation of L.f. 11976
L.f. 11976 microencapsulation was optimized-by controlling the 
flow rate, stirring time, stirring speed, coating time, vibration frequen-
cy, and voltage to obtain spherical and monodispersed microcapsules. 
The obtained L.f. 11976 microcapsules were observed under light mi-
croscopy at magnifications of 100X and 200X. The APA microcapsules 
were monodispersed with an approximate size of 602 ± 30μm in diam-
eter. Figure 1A demonstrates the spherical shape of the microcapsule 
and Figure 1B allows for the visualization of the outer coat of the APA 
microcapsule with the bacterial cells evenly distributed within the poly-
meric membrane.
Total antioxidant capacity of free and microencapsulated L.f. 
11976
To investigate the antioxidative potential of the FA produced by L.f. 
11976 and to ensure that the microcapsule does not inhibit this activ-
ity, a QuantiChromTM Antioxidant Assay Kit was used. Commercially 
purchased FA was shown to have significant antioxidant activity, with a 
linear correlation demonstrated using Trolox as the provided standard 
(R2 = 0.9881, p < 0.0001) (Figure 2A). To quantify the bacterial anti-
oxidant activity the probiotic strain was incubated in MRS-EFA at an 
initial EFA concentration of 1.5mM. Antioxidant activity and bacterial 
viability were measured at various time points for both free (Figure 2B, 
2C) and microencapsulated L.f. 11976 (Figure 2D, 2E). Following 48 
hours of incubation, the antioxidant activity of L.f. 11976 was 713.81 
± 3.72μM Trolox equivalents for the free cells and 699.52 ± 15.26μM 
Trolox equivalents for the microencapsulated cells. No significant dif-
ference in antioxidant production was detected between the free and 
microencapsulated cells (p = 0.450). Using the curve generated for 
FA the activity correlates to 1931.83 ± 10.07μM for the free cells and 
1893.15 ± 41.30 μM FA.
Effect of microencapsulated L.f. 11976 on body weight and 
adiposity
Dietary intake, food consumption and adiposity were monitored 
following the change to a hyperlipidemic hypercholesterolemic diet. 
The animals, of both groups, gained significant amounts of body weight 
over the course of the 10 week study (Figure 3A). Following the 10 
weeks of treatment, there was no significant difference in body mass be-
tween the control (157.20 ± 2.25g) and the treatment (151.42 ± 3.17g) 
animals (p = 0.178).In addition, no significant difference in food con-
sumption between the groups was observed (data not shown). As for 
the abdominal visceral fat weights, these were significantly lower in the 
animals treated with microencapsulated L.f. 11976.The adiposity index 
of the treated group of animals, at the end of the 10 weeks of treatment 
with microencapsulated L.f. 11976 (6.22 ± 0.25) proved to be signifi-
cantly lower than that of the control animals (7.94 ± 0.35) (p = 0.0014) 
(Figure 3B).
Effect of microencapsulated L.f. 11976 on serum glucose and 
insulin
Fasting serum glucose was monitored throughout the treatment pe-
riod and consumption of the hyperlipidemic hypercholesterolemic diet. 
Hamsters administered L.f. 11976 (15.41 ± 2.26 mmol/L) showed no 
significant decrease in fasting serum glucose level following 10 weeks of 
treatment, when compared to the untreated control hamsters (16.37 ± 
1.20 mmol/L) (p=0.629) (Figure 4A). On the other hand, serum fasting 
insulin concentrations were significantly different between animals ad-
ministered the microencapsulated bacterial formulation (0.59 ± 0.096 
ng/mL) and the controls (1.40 ± 0.217 ng/mL) (p = 0.0042) (Figure 4B). 
Moreover, intervention with the microcapsule formulation showed a 
significant reduction in insulin resistance (HOMA-IR) in treated ani-
mals (66.51 ± 10.78) as compared with the controls (153.86 ± 28.24) (p 
= 0.0096) (Figure 4C).
A B 
Figure 1: Morphology of APA microcapsules containing L.f. 11976 taken by 
light microscope (A) 100x and (B) 200x. The approximate diameter of the 
microcapsules was 602 ± 30μm in diameter.
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Figure 3: Effect of oral feeding of microencapsulated L.f. 11976  on the (A) 
animal mass over time and on the (B) adiposity index (**p < 0.01) follow-
ing 70 days of treatment in Golden Syrian hamsters. Data represents the 














































































Figure 4: Treatment of diabetic obese Golden Syrian hamsters with micro-
encapsulated L.f. 11976  resulted in a non-significant reduction in (A) serum 
glucose levels following 10 weeks of treatment, but showed a significant re-
duction in (B) serum insulin levels (**p < 0.01). (C) Insulin resistance was 
quantified using Homeostasis Model Assessment (HOMA-IR). The treated 
group showed HOMA-IR values significantly lower than untreated control 
































































































































Figure 2: Antioxidant activity of ferulic acid produced by L.f. 11976. (A) Com-
mercially purchased ferulic acid antioxidant activity correlated with Trolox 
concentration using a QuantiChromTM Antioxidant Assay Kit (R2 = 0.9881, p < 
0.0001). (B) Viability and (C) antioxidant production by free L.f. 11976 and (D) 
viability and (E) antioxidant production by APA microencapsulated L.f. 11976. 
Following 48 hours of incubation antioxidant activity of L.f. 11976 was 713.81± 
3.72μM Trolox equivalents for the free cells and 699.52 ± 15.26μM Trolox equiv-
alents for the microencapsulated cells (p = 0.450).
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Effect of microencapsulated L.f. 11976 on glycemic control 
and inflammation
Serum HbA1c levels were measured following 10 weeks of treat-
ment with microencapsulated L.f. 11976. HbA1c was non-significantly 
reduced in the treated group (8.41 ± 1.40 %) when compared to the 
control group (12.85 ± 1.59 %) (p = 0.058) (Figure 5A).On the other 
hand, a highly significant reduction in GA levels of the hamsters treated 
with microencapsulated L.f. 11976 (0.86 ± 0.12 %) when compared with 
the control animals (2.38 ± 0.30 %) was noted (p = 0.00013) (Figure 5B).
Systemic inflammation, as measured by serum CRP levels, was not 
found to be significantly different between the treatment (12.04 ± 4.05 
nmol/L) and control (16.27 ± 4.62nmol/L) animals (p = 0.61) (Figure 
5C). On the other hand, the serum concentration levels of uric acid, 
following 10 weeks of treatment, were found to be significantly higher 
in the control group (247.07 ± 23.02 μmol/L) when compared to the 
levels of the group administered microencapsulated L.f. 11976 (178.07 
± 15.32 μmol/L) (p = 0.025) (Figure 5D). A statistically significant dif-
ference in the serum leptin levels was also noted between the treated 
(143.54 ± 19.46 pg/mL) and the control (211.75 ± 24.33 pg/mL) ani-
mals (p = 0.048) (Figure 5E).
Effect of microencapsulated L.f. 11976 on serum lipids
Figure 6A demonstrates that, following 10 weeks of treatment 
with microencapsulated L.f. 11976, there was a significant decrease 
(p = 0.024) in serum TC concentrations in the treated (14.33 ± 2.38 
mmol/L) as compared to the control (23.18 ± 2.52 mmol/L) animals 
(p = 0.024). At the same time point, serum FC levels, did not show any 
difference between the treated (1.71 ± 0.31 mmol/L) and the control 
(1.55 ± 0.33 mmol/L) hamsters (p = 0.758). However, EC concentra-
tions were significantly reduced in the treated animals (12.91 ± 2.51 
mmol/L) when compared to the control animals (21.94 ± 2.83 mmol/L) 
(p = 0.0328).Figure 6B demonstrates that serum triglyceride (TG) con-
centrations were not significantly different between the treated (6.28 ± 
0.97 mmol/L) and the control (8.36 ± 0.51) groups (p = 0.0948). On the 
other hand, there was a significant reduction in serum NEFA concen-
trations in the treated animals (2.65 ± 0.12 mmol/L) as compared to the 
control animals (3.33 ± 0.26 mmol/L) (p = 0.029).
Discussion
Probiotics are dietary supplements containing bacteria which, 
when administered in adequate amounts, confer a health benefit on the 
host [14,20]. Probiotics, as natural compounds, are generally consid-
ered safe, but can also be tested for set-out safety parameters [21]. A 
number of studies have investigated bacterial strains for a range of con-
ditions, including infections, allergies and metabolic disorders such as 
ulcerative colitis and Crohn’s disease [14]. Promising research focuses 
on the microbial secretion and production of beneficial biologically ac-
tive enzymes and proteins, including: ornithine decarboxylase for the 
treatment of autoimmune diseases and accelerated cell apoptosis [22], 
bile salt hydrolase for hypercholesterolemia [23;24], and bile transport 
and tolerance proteins for the efficient delivery of probiotics [25]. In 
recent studies, the products of another microbial protein, cinnamoyl es-
terase, have shown significant levels of antioxidant activity [10,26] and 
other effects, including stimulation of insulin secretion [17,27], preven-
tion of oxidative stress [17], lipid peroxidation [28],cholesterol-lower-
ing capabilities [9] and inhibition of diabetic nephropathy progression 























































































































Figure 5: Changes in (A) serum HbA1c,(B) serum GA (***p < 0.001),(C) se-
rum CRP,(D) serum uric acid (*p < 0.05) and (E) serum leptin (*p < 0.05) lev-
els in hamsters treated with microencapsulated L.f. 11976. Data represents 



























































Figure 6: Clinical effects of microencapsulated L.f. 11976 on lipid metabolism 
in Golden Syrian hamsters; (A) serum total cholesterol (*p < 0.05), serum free 
cholesterol and esterified cholesterol (*p < 0.05) and (B) serum triglycerides 
and non-esterified (free) fatty acids (*p<0.05). Data represents the mean ± 
SEM (n = 12).
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FA is a naturally found phenolic acid that has numerous beneficial 
properties. Recent studies suggest that FA has antitumor activity against 
breast cancer [30,31], liver cancer [32,33] and is effective at preventing 
cancer induced by the exposure to carcinogenic compounds such as 
benzopyrene [34] and 4-nitroquinoline 1-oxide [35]. FA has also been 
demonstrated to have important antioxidant properties [1] while also 
reducing cell aging [2]. Keeping this in mind, we propose that FA can 
be used to modulate a number of biomarkers related to metabolic syn-
drome, specifically cardiovascular diseases, T2DM and obesity (Figure 
7). Unfortunately, the oral delivery of free FA is hampered by its quick 
absorption in the jejunum, followed by its rapid excretion [36]. It has 
been demonstrated in a number of recent studies that some GIT bacte-
rial strains produce FAE, an enzyme that can produce FA from natural 
substrates. The oral delivery of these bacteria, however, is impeded by 
the harsh conditions of the upper GIT, specifically the presence of bile 
and an acidic pH. Microencapsulation, specifically APA microencap-
sulation, has been successfully used to overcome the challenge of de-
livering bacterial cells through the GIT [11]. APA microencapsulation 
relies on a polyelectrolyte complexation mechanism for the association 
of alginate and PLL. Alginate is a natural biocompatible polymer, ex-
tracted from brown algae, that is increasingly being used in the bio-
technology industry [14]. Alginate is an unbranched polysaccharide 
containing 1,4′-linked β-D-mannuronic acid and α-L-guluronic acid 
blocks interdispersed with regions of the alternating structure, β-L-
mannuronic acid-α-L-guluronic acid blocks. PLL is a polypeptide made 
up of the amino acid L-lysine that is available in a variable number of 
chain lengths. The addition of this polymer leads to the formation of a 
capsule membrane that provides selective permeability and immuno-
protection. The alginate bead could not withstand the harsh conditions 
of the GIT in the absence of PLL, which provides it with an increased 
mechanical stability. Previous research, by our group, investigated APA 
microencapsulation as a method to protect bacterial viability through a 
GIT transit, and demonstrated a significant 2.5 log difference in viabil-
ity between free and APA microencapsulated L. fermentum following 
transit [11].
Previous research by our group has screened for FA production by 
probiotic bacteria [7,10]. For this research, L.f. 11976 was selected for 
its FAE activity. In vitro studies into the antioxidant properties of this 
strain were performed with relation to FA production. Following 48 
hours of incubation, the antioxidant activity of L.f. 11976 was deter-
mined and correlated with a standard curve generated for FA. Using 
the curve generated for FA the activity correlated to 1931.83 ± 10.07μM 
for the free cells, greater than that quantified by previous HPLC assays 
[7,10]. These results suggest that the antioxidant activity of L.f. 11976 
may not be explained solely by its FA production, but by potential other 
molecules produced by this strain, which require further investigations. 
The demonstrated antioxidant activity as well as its previously demon-
strated effects on hypercholesterolemia make it an ideal candidate for 
this study [7].
Feeding of a high lipid diet provides a dietary model of metabolic 
syndrome-cardiovascular diseases, T2DM and obesity-similar to that 
of a Western Diet. A number of risk factors are involved in metabolic 
syndrome, including insulin resistance, hyperglycemia, hyperinsu-
linemia, chronic systemic inflammation and hypertriglyceridemia, to 
name a few. An overload of fat to the liver leads to the disruption of 
metabolic and glucose uptake pathways, potentially leading to an en-
hanced rate of de novo lipogenesis and triglyceride synthesis, ultimately 
Figure 7: FA is proposed to modulate markers of metabolic syndrome, presenting a number of different mechanisms of action by which it can prove ben-
eficial. Probiotic microcapsules, in the ascending colon, release FA due to FAE enzymatic activity, leading to the systemic absorption of FA. FA has been 
shown, in the presented research and in other works, to modulate a number of markers that play an important role in metabolic syndrome-cardiovascular 
diseases, obesity and T2DM.
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inducing insulin resistance. The presented study uses a hamster model 
fed a hyperlipidemic hypercholesterolemic diet, leading to the induc-
tion of moderate insulin resistance and elevation of serum glucose. Fu-
ture research may also want to investigate to what extent markers of 
metabolic syndrome are restored following probiotic treatment, using 
a comparative group fed a standard diet. One could also investigate the 
potential effect(s) of treatment on animals consuming a standard diet.
Following 10 weeks of treatment with APA microencapsulated L.f. 
11976 the serum glucose levels were only numerically disparate in the 
treated animals when compared to the control group. Furthermore, no 
significant difference in animal body mass was noted, suggesting that a 
longer treatment period may be necessary to significantly alter hyper-
glycemia and obesity. On the other hand, insulin levels were significant-
ly lower in the treatment group than the control, suggesting a control 
of hyperinsulinemia by the probiotic formulation. In addition, insulin 
resistance, as determined using HOMA-IR, was alleviated significantly 
(p = 0.0096), demonstrating the ability of microencapsulated L.f. 11976 
to improve the sensitivity of the peripheral tissues to insulin.
The United Kingdom Prospective Diabetes Study demonstrated 
that a 1% reduction of HbA1c is associated with a 35% reduction in 
macrovascular endpoints, an 18% reduction in myocardial infarction, 
and a 17% reduction in all-cause mortality [37]. In our study, the HbA1c 
levels, following 10 weeks of treatment, demonstrated only a non-sig-
nificant difference(8.41 ± 1.40 %) for the treated and (12.85 ± 1.59 %) 
for the control animals (p = 0.058). One must keep in mind, however, 
that total HbA1c reveals the percentage of circulating hemoglobin that 
has chemically reacted with glucose, reflecting the blood glucose levels 
over the 120 days preceding the test [38], and is, therefore, unaffected 
by short term fluctuations in blood glucose levels present in a short (70 
days) study like this one. Furthermore, the non-significant decrease in 
HbA1c levels observed in our study may reflect the need for the longer 
administration or a higher dose of probiotic to demonstrate an ade-
quate and long-term reduction of hyperglycemia.
Serum GA levels have been shown to be a better alternative marker 
of glycemic control in patients with T2DM [39] since it is free of in-
terference from endogenous glycated amino acids and is unaffected by 
changes in albumin concentration. In the presented study, hamsters 
treated with microencapsulated L.f. 11976 demonstrated significantly 
lower GA concentrations than the control group (p = 0.00013). Further-
more, control animals had significantly increased TC, TG, and NEFA 
levels. Dyslipidemia is often one of the first risk factors identified and 
observed in pre-diabetic patients [40], suggesting a link between dys-
lipidemia and T2DM initiation. For example, it has been reported that 
GA contributes to dyslipidemia in diabetes (and renal insufficiency) 
[41] and GA modification impairs the Low-Density Lipoprotein (LDL) 
receptor-clearance mechanism [42]. Hence, even a small decrease in 
GA (such as that observed in this study) and TC, TG and NEFA levels 
may be sufficient to stop the triggering of pathogenic mechanisms un-
derlying accelerated atherosclerosis, nephropathy and retinopathy [43]. 
Future studies should take into consideration that GA measurements 
reflect glycemic control for only two weeks preceding the assay, and so 
should be taken more frequently throughout the study.
Our results demonstrate a significant reduction in serum NEFA 
levels in the animal group treated with microencapsulated L.f. 11976, 
following 10 weeks of treatment (p = 0.029). Recent studies support 
the idea of a correlation between elevated NEFA and peripheral insulin 
resistance [44]. In obese individuals, serum NEFA levels are chronically 
elevated, contributing to insulin resistance at the skeletal muscle level. 
Furthermore, these may have additional actions in the liver and pan-
creas, contributing to the development of T2DM [45]. Hence, NEFA 
consist of an important therapeutic target that our probiotic formula-
tion successfully modulated.
The administration of microencapsulated L.f. 11976 also reduced 
the accumulated levels of advanced glycosylation end-products, pro-
duced by non-enzymatic glycosylation of proteins (Maillard reaction) 
[46], as indicated by the decrease in total HbA1c and albumin. Glyco-
sylated end-products are present in high levels in T2DM patients, stim-
ulating macrophages to secrete inflammatory cytokines and growth 
factors, impairing normal macrophage function, hence, increasing sus-
ceptibility to infection [47]. Similarly, inflammatory markers, particu-
larly CRP, play an important role in cardiovascular disease as they are 
linked with an increased risk of atherosclerosis, myocardial infarction 
and diabetes [48,49]. These findings suggest an association between 
glycemic control and systemic inflammation in people with established 
diabetes, specifically with HbA1c levels [48]. In the presented study, 
administration of microencapsulated L.f. 11976 decreased slightly, al-
though not significantly, serum CRP levels (p = 0.61), which may be 
explained by the high levels of HbA1c observed.
Hyperuricemia also demonstrates a strong correlation with insulin 
resistance, and cardiovascular disease, but not with blood glucose levels 
[50]. The link between insulin resistance and hyperuricemia, elucidated 
by Facchini et al. demonstrates that urinary uric acid clearance decreas-
es in proportion to an increase in insulin resistance, manifesting as an 
increase in serum uric acid concentrations [51]. Our results demon-
strate simultaneous reduction of serum uric acid and insulin resistance 
in hamsters receiving microencapsulated L.f. 11976 when compared to 
control animals. Previous research has also noted that elevated serum 
leptin levels, a neuroregulatory peptide that regulates lipid, glucose and 
insulin, contribute to increased serum uric acid levels [52]. A major-
ity of patients with T2DM have elevated leptin levels, associated with 
that seen in obese subjects [53]. In our study, there was no significant 
difference in body weight (p = 0.178) between the treated and control 
animals, even though the serum leptin levels were significantly lower in 
the treated animals (p = 0.0476). Previous research has demonstrated a 
strong positive correlation between serum leptin concentration and the 
percentage of body fat, as we also demonstrate with a decreased adi-
posity index [53]. As aforementioned, despite the difference in serum 
leptin levels, no significant difference in food consumption or body 
mass was noted between the two groups. Previous research has dem-
onstrated that obese subjects may have decreased sensitivity to leptin 
and require larger doses of leptin to induce weight loss, explaining the 
phenomena seen in the presented work [53].
The consumption of functional foods containing probiotics has 
been proposed as one of the best approaches to treat and/or inhibit the 
prevalence of T2DM, obesity and cardiovascular diseases. It has previ-
ously been demonstrated that probiotic lactic acid bacteria can con-
trol glucose levels and significantly delay the onset of hyperglycemia, 
hyperinsulinemia, dyslipidemia, glucose intolerance and oxidative 
stress [54,55]. The supplementation of probiotic L. acidophilus and L. 
casei with dahi cultures, increased the efficacy of dahi in suppressing 
streptozotocin-induced diabetes in rats by inhibiting insulin depletion, 
diabetic dyslipidemia, lipid peroxidation and nitrite formation [54]. 
FA-producing microencapsulated lactic acid bacteria have been shown 
to liberate FA in the gut [8,11]. Currently, it is not clear exactly how FA 
is impacting metabolic syndrome, as presented in this study. However, 
as shown in Figure 7, the mechanism(s) of action by which FA exerts 
its beneficial effects has been hypothesized, with a number of biomark-
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ers involved that play important roles in metabolic syndrome. Future 
research should focus on the potential mechanisms of action and fur-
ther explore the role of FA in all of the markers presented. The exact 
role of FA in modulating the markers described in this research will be 
investigated further using both in vitro and in vivo studies, focusing on 
both the metabolic and anti-inflammatory effects of this molecule. The 
objective of this research was to demonstrate the use of a FA-producing 
probiotic on the modulation of metabolic markers, with mechanistic 
studies to follow. Future animal work should also be undertaken using 
other models of metabolic syndrome and T2DM.
Conclusion
The presented study investigated the effects of feeding microencap-
sulated live probiotic L.f. 11976 on biomarkers of metabolic syndrome, 
entailing cardiovascular diseases, obesity and T2DM. The evidence for 
a possible role of dietary FA for the treatment and prevention of these 
disorders is presented and discussed. Keeping in view the gaps in these 
studies, the various mechanisms by which FA may improve the control 
of glucose tolerance, lipid metabolism, body mass and other markers 
presented here, need to be further investigated.
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